Cooperative Agreement U48DP006836

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,994,888 Cooperative Agreement under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Research Triangle Institute (RTI International) to establish and maintain the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (REVAMPP) Coordinating and Data Sharing Center (CDSC). The CDSC will coordinate the REVAMPP network, comprised of 6-8 research centers, to...

This $401,250 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the causes and mechanisms of antibiotic-associated reactions (AAR), including serum sickness-like reactions (SSLR), in pediatric patients. The project aims to improve understanding of the role of innate immunity and gut microbiome dysbiosis in the development of these adverse...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $721,721 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Los Angeles (UCLA). The grant will fund the UCLA RAPID, RIGOROUS, RELEVANT IMPLEMENTATION SCIENCE HUB to provide technical assistance, coaching, and consultation to support implementation science research projects focused on improving HIV outcomes. Over the 5-year period from August 1, 2025...

This Cooperative Agreement award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to define the molecular determinants of durable versus non-durable antibody responses in vaccinated individuals. The $777,495 award to the University of Maryland, Baltimore will support a clinical trial to characterize antibody-secreting cell populations and their antibody production over time in response to...

This federal Cooperative Agreement award of $825,857 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides funding to Health Research, Inc. (d/b/a Health Research At Roswell Park) to serve as the Data and Resource Coordinating Center for the Cancer Immunoprevention Network (CIP-NET). The goal is to catalyze collaboration across CIP-NET and manage, integrate, and disseminate the data and resources generated through the network....

This Cooperative Agreement award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the mechanisms of early-life immunity associated with HIV-1 vaccine-induced neutralizing antibody responses in pediatric populations. The $1,239,565 award to Duke University will fund a 5-year project to study an innovative pediatric vaccine regimen using HIV-1 envelope immunogens...

This $4,211,839 Cooperative Agreement, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, aims to develop a germline-targeting priming immunogen for the HIV envelope V2-apex broadly neutralizing antibody (BNAB) site. The project, titled "Rationally Designed Targeted Immunogens to Elicit HIV Envelope V2-Apex Broadly Neutralizing Antibodies", will test the immunogen's ability to activate...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,874,388 Cooperative Agreement under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Duke University. The award, effective June 13, 2025, supports the "Center for Multiscale Immune Systems Modeling" (the Center of Excellence) - a multi-disciplinary research initiative focused on developing innovative solutions for multi-scale modeling in infectious and immune-mediated...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,225,986 Cooperative Agreement on January 23, 2025 to the University of Chicago under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project aims to develop computational models that describe the conditions under which strong, durable, and broadly protective adaptive immune responses to influenza vaccination arise, particularly in individuals with prior exposure to the virus....